
- 3 days ago
William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

- Nov 22
SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

- Nov 20
Sofinnova Investments' Jakob Dupont on the private markets in biotech

- Nov 16
BMO's Evan Seigerman joins Analyst Thursdays from London

- Nov 9
Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

- Nov 7
PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria

- Nov 7
An AI expert describes how machine learning is changing drug development

- Nov 7
The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

- Nov 7
Tvardi Threrapeutics' CEO on targeting STAT3

- Nov 7
Everything drug developers need to know about CPRIT oncology grants

- Nov 7
UTMB's President discusses his institution, and comments on the chronic kidney disease field

- Nov 7
The director of Rice's Biotech Launchpad describes technologies that are being turned into companies

- Nov 7
Texas Medical Center's CEO talks about Houston's new TMC Helix Park

- Nov 7
BioHouston CEO Ann Tanabe kicks off the 2023 Texas Life Science Forum

- Nov 5
Y-Trap's Rishi Bedi on how predictive & generative AI are changing drug development

- Nov 5
Dan Chen's closing takeaways from #SITC23

- Nov 4
Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

- Nov 4
The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells

- Nov 4
Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23

- Nov 3
SITC Biotech Strategic Initiative Co-Chair Kristen Hege on the IO field